Text Link
Industry Dive's Dive D Icon
Industry Dive's Dive D Icon

Biotech's New Normal

Challenges and Opportunities
Recorded
Nov 13, 2024
Nov
, 
2024
2-5pm ET
Virtual event on-demand
Virtual event
Register for free

Biotech's New Normal

Challenges and Opportunities
Recorded
Nov 13, 2024
2-5pm ET
Virtual event
Register for free

In this virtual event, BioPharma Dive journalists will discuss the emerging biotech ecosystem with executives, venture investors and industry experts, building on our award-winning coverage of the sector.

Over three panels, we will explore the financial and operational challenges facing early-stage drug companies and their backers. Attendees will also get to hear the latest on the scientific catalysts that are fueling the formation of new startups.

Who should attend?

  • Executives and employees at early-stage biotech companies
  • Partners and associates at biotech venture capital firms
  • Executives and employees at pharmaceutical company venture arms, or who are involved in private company business development
  • Executives and employees at biotech incubators
  • Other professionals or researchers in the space

Register for free

Watch now











Success

Your seat has been reserved! Please check your email for a registration confirmation and more information on how to access the event.

Event powered by

No items found.

Agenda

Biotech’s New Normal virtual event will give attendees the full spectrum on the state of biotech companies today, from the private and public financing landscape, to the construction and strategy of the companies, and the new momentum building in therapeutic areas like immunology and neuroscience.

Sessions

Join us for these engaging sessions with our editorial team and industry experts:

Session 1 Financing Biotech Startups This panel discussion will feature biotech executives and venture investors discussing the current environment for funding new drug companies, both privately and as those companies advance toward public markets. Sponsored session Enabling Emerging Biotechs With Supply With Care Enabling Emerging Biotechs With Supply With CareEmerging biotechs face unique challenges in navigating the complexities of the pharma supply chain, including regulatory compliance, supply chain transparency, and logistical barriers. By offering specialized clinical trial management, advanced technologies, and dedicated partnership, we enable biotechs to overcome these obstacles. Our commitment to investment ensures biotechs receive the support needed at every stage, empowering them to bring innovative therapies to patients efficiently and effectively - all with Supply with Care by Almac Clinical Services. Presented by Almac Group Session 2 Building Biotechs to Last While the biotech sector has stabilized after last year’s downturn, companies still face a difficult environment. How is that affecting their strategy and plans for growth? Join this panel discussion to hear from executives navigating these challenges. Session 3 New Areas of Research Momentum Scientific advances are opening up opportunities for new types of medicines, such as for those that treat diseases of the brain and immune system. In this panel discussion, you’ll hear from venture investors tasked with making bets on promising research and from drug company executives tasked with turning that potential into reality.

Questions

If you have questions about registration, if you’re interested in speaking, or have any other questions, contact us at events@industrydive.com.

Speakers

Chris Bardon // Co-managing Partner // MPM BioImpact
Abbie Celniker // Partner // Third Rock Ventures
Peter Flynn // CEO // Arialys Therapeutics
Michael Gilman // CEO // Arrakis Therapeutics
Nina Kjellson // General Partner // Canaan Partners
Kevin Marks // President and CEO // Delphia Therapeutics
Andrew Miller // Chairman // Progentos Therapeutics
Ken Song // CEO // Candid Therapeutics
David Yang // Investor // Lux Capital
Jacob Bell // Senior Reporter // BioPharma Dive
Ben Fidler // Senior Editor // BioPharma Dive
Gwendolyn Wu // Reporter // BioPharma Dive
Paul O'Connor // {{Presented by Almac Group}} // Global VP, Quality // Almac Clinical Services
Richard Segiel // {{Presented by Almac Group}} // VP, Business Development // Almac Clinical Services

BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.

BioPharma Dive is a leading industry publication operated by Industry Dive, an Informa business. Industry Dive’s business journalists spark ideas and shape agendas for 15 million decision makers in 20+ competitive industries.